Lonza grows hepatocytes portfolio

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/vshivkova)
(Image: Getty/vshivkova)
Lonza has added to its hepatocytes portfolio to provide researchers with the foundation to create “more physiologically relevant” in vitro models for liver disease research.

The expanded portfolio now includes hepatic stellate cells, Kupffer cells, and liver-derived endothelial cells, according to the company.

“There are many transformative efforts ongoing to create and validate in vitro human models for better diagnostics and treatments of liver disease and toxicity,”​ Maureen Bunger, PhD, product manager, ADME/tox solutions, Lonza Biosciences, told us.

Offering high quality Kupffer, stellate, and liver endothelial cells in addition to hepatocytes in support of these models can accelerate the impact they may have on human health,”​ she added.

Hepatic non-parenchymal cells are involved in normal liver function, including transport, metabolism and growth – and also play a role in the immune response. 

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related products

show more

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Clear Guidelines for IND/CTA

Clear Guidelines for IND/CTA

Altasciences | 24-Feb-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Follow us


View more